Next 10 |
home / stock / lgnd / lgnd articles
Shares of Ionis Pharmaceuticals (NASDAQ: IONS) and Biogen (NASDAQ: BIIB) lost at least 2% in market cap on Thursday after the companies announced t...
On May 15, a recent SEC filing unveiled that Matthew E Korenberg, President & Chief Operating at Ligand Pharmaceuticals (NASDAQ:LGND) made an i...
Merck (NYSE: MRK) announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor...
Perrigo Company plc (NYSE: PRGO) reported adjusted earnings of 29 cents per share in the first quarter of 2024, beating the Zacks Consensus Estimat...
A significant insider transaction involving the exercise of company stock options was reported on March 27, by Todd C Davis, Chief Executive Office...
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) reported fourth-quarter 2023 sales of $28.1 million, beating the consensus of $25.72 mi...
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. Helix Energy posted ...
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Shares of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) ...
Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent&n...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Shares of Ionis Pharmaceuticals (NASDAQ: IONS) and Biogen (NASDAQ: BIIB) lost at least 2% in market cap on Thursday after the companies announced t...
On May 15, a recent SEC filing unveiled that Matthew E Korenberg, President & Chief Operating at Ligand Pharmaceuticals (NASDAQ:LGND) made an i...
Merck (NYSE: MRK) announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor...